Cellceutix Autism Research Demonstrates Increase in Serotonin Levels in Three Areas of the Brain

BEVERLY, MA–(Marketwire – June 23, 2010) –  Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that they have completed another study in the research of KM-391, their novel compound being developed to treat the core symptoms of autism. Cellceutix is pioneering research in autism treatments and has been making solid progress with pre-clinical research as announced in previous press releases.

Neonatal serotonin depletion and decreased brain plasticity are established observations in the autistic brain. The Cellceutix team has identified a reliable animal model and has been successful in chemically inducing these characteristics in the model. The data collected to this point has been promising as KM-391 has shown to be successful in altering the serotonin and brain plasticity levels resulting in physical and behavioral changes in the model that are similar to the “non-autistic” control groups.

The latest research involved physical measurements of serotonin levels in the cerebral cortex, hippocampus, and caudate nucleus areas of the brain. Several groups of rats were established with two of the groups being injected to induce the symptoms of autism. After 48 days, the brains were assayed for serotonin by ELISA with the data showing that the administration of KM-391 significantly increased serotonin levels in all 3 regions of the brain: cerebral cortex, hippocampus, and caudate nucleus, from very low levels as observed with the induced autism to normal levels as observed in placebo treated control which received no treatment. More detailed information on the research is available at www.cellceutix.com.

George Evans, Cellceutix Chief Executive Officer, commented, “This new data is highly relevant as it reinforces the data from previous studies and further solidifies our contention that serotonin levels in multiple brain regions may be a necessary key to the next generation of autism treatments.”